Kennedy.
The FDA is currently reviewing a 90-day implant intended for use as
an alternative to revision surgery for patients who suffer a recurrence of
polyps, says Dr. Kennedy. He believes the real excitement about the
future use of drug-eluting implants lies in what agents could be added to
them — such as a monoclonal antibody for immunization of mucosal
surfaces or a local anesthetic to help manage pain following tonsillecto-
my — to prevent recurrence of symptoms and treat patients healing
from surgery.
OSM
J U N E 2 0 1 6 • O U T PA T I E N T S U R G E R Y. N E T • 1 0 3
